Research published in the Journal of Medical Internet Research (JMIR) Diabetes investigating the effectiveness of the Fitterfly Diabetes CGM digital platform demonstrated an improvement in blood sugar control and reduction in weight.
Mumbai, India-based Fitterfly’s digital therapeutics programme is delivered over 90 days and provides personalised feedback and support for people living with type 2 diabetes. It is delivered through continuous glucose monitoring (CGM) technology coupled with a mobile application.
The patient’s data are initially assessed by nutritionists, physiotherapists, and psychologists and correlated further manual data from the app, including food logs, activity regimes, sleep, and medication.
Artificial intelligence and machine learning predictive models can then create a personalised approach to managing blood sugar longer term through behavioural changes.
CGM use is growing in patients as technological advancements provide increasingly accurate feedback for glycaemic management. A market model by GlobalData estimates that by 2030, the global CGM market will be worth just over $2bn, up from $600m in 2015.
The study analysed 109 participants living with type 2 diabetes over a 90-day. At the end of the 90 days, haemoglobin levels (the primary outcome of the study) were significant reduced. Weight and body-mass-index (BMI) were also significantly reduced and average blood glucose levels showed a significant mean reduction.
The study also found that participants who engaged more with the mobile app had better clinical outcomes, especially in weight reduction. Mobile apps are becoming more engrained in the scaffold of personal health management and GlobalData predicts the market will reach $12.1bn by 2030.
“Type 2 diabetes is a huge health care concern in India. With the use of newer tools such as digital therapeutics now getting adopted by people and enterprise partners, and getting prescribed by physicians, we are bridging the gap for behavior change. The study affirms our belief that digital therapeutic programs can provide clinically validated outcomes and help the population at scale,” said Dr Arbinder Singal, CEO and co-founder of Fitterfly.